Investment Banking

Noble Financial's investment banking team has a singular focus: to exceed our client's expectations by providing the appropriate advice and execution necessary for efficient capital raising, mergers & acquisitions advisory and capital markets support. We leverage our fundamental sector research expertise in healthcare, natural resources, technology, media and telecom, along with our firm's three-decade history of capital markets acumen, in the creation of a customized solution for our clients.

Our investment banking team, together with our well-recognized equity research analysts and the equity capital markets group, provide our clients with fundamental capital markets advisory and support - prior, during and most importantly, after a transaction.

IB Services

Noble Financial's investment banking team works closely with the management and Board of our corporate clients in order to fully understand operational and financial objectives. With this knowledge our banking team will develop an efficient and effective advisory program which offers a variety of services including:

  • Capital Markets Support
  • Block Trades
  • Mergers & Acquisitions (Buy and Sell-Side)
  • Restructuring & Recapitalizations
  • Sale or Divestitures

Noble Financial's investment banking team is able to achieve transactional success for our clients by tapping into our resident expertise in our research verticals, and through our long-standing relationships with leading institutional investors. Noble Financial is routinely involved in the following Corporate Finance transactions:

  • Initial Public Offerings (IPOs)
  • Alternative Public Offerings (APOs)
  • Follow-on Offerings
  • Private Placement in Public Companies (PIPE's)
  • Private Placements in Private Companies
  • At The Market Transactions (ATMs)

Merchant Banking

Our Principal Investment focus is primarily on private and small-cap public ($10mill to $50mill market caps) companies in industries within Noble's research verticals. Investments are made directly by Noble and its affiliates and may also involve syndicate participants. We work to identify those companies with game-changing or superior products and technologies that have management teams with proven track-records of success. Noble structures investments to meet a company's capital needs whether its growth capital, liquidity or debt repayment. Capital commitment ranges from $200k to $2million principal and $2million above with syndicate.

The scope of our Merchant Banking activities includes:

  • Targeting domestic companies within our areas of focus and expertise
  • Analyzing a company's opportunities and assessing its risks within their respective industry
  • Structuring, negotiating and executing the transaction
  • Work in assessing the appropriate time and manner in which to harvest the investment

Post Transaction Support:
Noble's Merchant Banking Team works continuously with our portfolio companies to assist the management team and Board of Directors to create value and grow their businesses to facilitate long-term shareholder value. Through our extensive sector research coverage, institutional investor non-deal road shows, equity conferences and market making, we blend a powerful mix of capital markets acumen to procure success.

Transactions

Noble's Investment banking team has, on average, more than 25 years' experience in the industry. Transactions drive our business. Building a solid foundation of mutual respect and trust with our customers drives transactions. Here is a selection of some of the companies we've helped over the years.

Life Sciences Advisory Board

Our Life Sciences Advisory Board (LSAB) is a strategic resource whose experience, relationships and knowledge are utilized throughout NOBLE Life Science Partners to enhance all service offerings. Through the LSAB, we have access to world-class healthcare professionals for substantive advice regarding new discoveries, technologies, products, services and developments.

Our LSAB is a powerful client offering unique to NOBLE Life Science Partners.

  • Equity Research − enriches our research offerings and expertly positions capital markets deals
  • Institutional Investors − provides solid market insight and unique perspectives
  • Corporate Clients − guides business formation and growth through meaningful assistance with strategic and tactical decisions
  • Assessment of existing products and new product launches
  • Identification of drug development targets, while applying an extensive reach in both Europe and the United States
  • Hands-on guidance in executing licensing opportunities with large-cap companies
  • Strategic market analysis with a goal of identifying the most favorable market opportunity

Noble Client Testimonials

We take great pride in our client relationships. And we’re proud to share the observations of those who know best what it’s like to work with Noble Financial Capital Markets.

Investment Banking Team

Shawn Titcomb

Managing Director / Head of Healthcare Investment and Merchant Banking

Department:
Investment Banking

E: stitcomb@noblelsp.com
T: (561) 998-5480
VCard: Shawn Titcomb

Mr. Titcomb joined Noble in 2006 and has close to fifteen years of experience in the various aspects of the healthcare capital markets. During his career he has worked at Variant Research Corporation as a founding partner, Avalon Research Group and UBS where he specialized in healthcare institutional sales as well as advising public and privately-held biotechnology, medical technology, and healthcare services companies. In addition, he has built an extensive network of institutional investors primarily focused on emerging healthcare companies. Mr. Titcomb holds a B.S. in Business Administration from the University of Denver, as well as various FINRA licenses.

Shawn Titcomb, Managing Director / Head of Healthcare Investment and Merchant Banking

Richard Giles

Managing Director / Head of TMT and Natural Resources Investment Banking Group

Department:
Investment Banking

E: rgiles@noblefcm.com
T: (617) 692-9346
VCard: Richard Giles

Mr. Giles brings to Noble Financial Capital Markets more than 30 years of investment banking and capital markets experience. Most recently Mr. Giles was head of the technology group at Stifel Nicolaus and prior to that spent 16 years at A.G. Edwards as head of its emerging growth group that included both Edwards' technology and healthcare practices. During his career he has executed over 100 public financings raising over $4 billion for his clients, including IPOs for companies such as VMWare, COMPAQ, Cardica and ExecuStay. He also has overseen numerous M&A transactions on the buy side as well as the sell side. Mr. Giles received his AB from Harvard College and his MBA from the Harvard Business School. Mr. Giles holds various FINRA licenses and works out of the company's Boston Office.

Richard Giles, Managing Director / Head of TMT and Natural Resources Investment Banking Group

John Cooleen

Managing Director Investment Banking, Head of Private Placements

Department:
Investment Banking

E: jcooleen@noblefcm.com
T: (610) 945-6460

Mr. Cooleen has dedicated his Twenty year career to serving as a trusted advisor in the brokerage and investment banking industry. He has extensive experience in growing new business as well as building existing investment banking, sales, and capital markets relationships. Deal experience gained while working on over 100 transactions including Follow-on Equity Offerings, Registered Direct Offerings, Shelf Takedowns, Initial Public Offerings, Confidentially Marketed Public Offerings, Private Investment in Public Equity, Private Placements, and Convertible Debt.

John Cooleen, Managing Director Investment Banking, Head of Private Placements

Cosme Ordoñez MD, PhD

Managing Director of Healthcare Investment Banking

Department:
Investment Banking

E: cordonez@noblefcm.com
T: (561) 998-5487

Dr Ordoñez joined Noble in 2016. He has sixteen years of experience in various segments of the healthcare capital markets. Recently, he was President and co-founder of Ciclofilin Pharmaceuticals, a San Diego based-biotechnology company, which was sold to ContraVir Pharmaceuticals. During his career, he has worked on various roles in Buy-side and Sell-Side Institutions, including Difference Capital Financial Inc., and GMP Securities Inc. in Canada. Dr Ordoñez has advised and helped raise funds for North American companies in drug development, medical device, specialty pharma and healthcare services areas. He is a Medical Doctor and obtained a Ph.D in Experimental Medicine and Biochemistry from McGill University in Montreal, Canada. He also completed post-doctoral training at the Karolinska Institute/Hospital in Stockholm, Sweden.

Cosme Ordoñez MD, PhD, Managing Director of Healthcare Investment Banking

Christopher Ensley

Managing Director, Investment Banking

Department:
Investment Banking

E: censley@noblefcm.com
T: (646) 790-5873
VCard: Christopher Ensley
LinkedIn: Christopher Ensley

Christopher Ensley is a Managing Director of technology, media & telecom (TMT) investment banking at Noble Financial Capital Markets where he focuses on capital raising, mergers and acquisition advisory and valuation opinions for clients. During his tenure on Wall Street, Mr. Ensley has participated in over $16B in transactions. Prior to Noble, Mr. Ensley was a TMT investment banker at Coady Diemar Partners, a boutique investment bank in NYC. Prior to Coady Diemar, Mr. Ensley was a Managing Director in the equity research department at Bear Stearns. While at Bear Stearns, Mr. Ensley was a member of the #1 rated broadcast equity research team for six straight years (2002-2007). Mr. Ensley was a Vice President of equity research covering the broadcast sector at Lazard. He began his Wall Street career as an equity research analyst at Salomon Brothers where he covered the tower industry in addition to the broadcasting industry. He received an MBA from Vanderbilt University and a BA from the College of William & Mary.

Christopher Ensley, Managing Director, Investment Banking

Nathan Cali

Managing Director of Healthcare Investment Banking

Department:
Investment Banking
Healthcare

E: ncali@noblefcm.com
T: (561) 994-5723
VCard: Nathan Cali

Nathan Cali has more than nine years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali's publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics ), medical devices, and regenerative medicine. He has been quoted in most business journals including Reuters, BioMedReports and the Washington Business Journal. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining Noble Financial, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 86, and 87 FINRA designations.

Nathan Cali, Managing Director of Healthcare Investment Banking

Francisco Penafiel

Vice President, Investment Banking

Department:
Investment Banking

E: fpenafiel@noblefcm.com
T: (561) 994-5740
VCard: Francisco Penafiel

Francisco Penafiel joined Noble Financial in 2002 after earning his Master of Science in Economics, with concentrations in Finance and International Economics from Florida Atlantic University. He obtained his undergraduate degree from Escuela Superior Politecnica in Ecuador, where he double-majored in Statistics and Computing Science. Prior to joining the investment banking department at Noble in 2011, Francisco was part of Noble's research department, working as a supervisory analyst and equity research analyst covering the enterprise/infrastructure software and business services industries. Other responsibilities included portfolio managing, computer modeling analysis and statistical review. He is also a member of the Company's Investment Policy Committee. Francisco holds various FINRA licenses and is a candidate in the CFA program.

Francisco Penafiel, Vice President, Investment Banking

Juan Arvelo

Director, Investment Banking

Department:
Investment Banking

E: jarvelo@noblefcm.com
T: (561) 994-5731
VCard: Juan Arvelo

Mr. Arvelo has more than 18 years of corporate finance and capital markets experience, with a special focus on M&A, restructuring and capital raising transactions. Mr. Arvelo has successfully completed equity placements, MBO’s, restructurings and M&A assignments in USA, Latin America and Africa. Prior to joining Noble Financial, Mr. Arvelo worked as Director at Enkeros Investments and Activa Capital Markets, and has been Director (BOD), Financial Advisor and interim officer for various companies, with main focus in the QSR, financial institutions and energy sectors. After finishing his Masters in Finance, Mr. Arvelo joined the corporate finance and recoveries division at PricewaterhouseCoopers (PwC), and was responsible for M&A transactions, Corporate Valuation Consulting Services, Project Finance, Privatizations and Dispute Analysis & Investigations. Mr. Arvelo graduated in Economics from Universidad Catolica Andres Bello (B.A. 1993), holds a Masters in Finance from IESA (M.A. 1997) and also graduated Magna Cum Laude from the MBA program at Babson College, with a majors Entrepreneurship and Strategy (M.B.A. 2004).

Juan Arvelo, Director, Investment Banking

Life Sciences Advisory Board Members

Victor Hartmann, MD

Chairman Life Sciences Advisory Board

Dr. Victor Hartmann was formerly the head of Corporate and Strategic Development at Vertex Pharmaceuticals, head of the Business Development and Licensing and head of Global Project Management at Novartis Pharma AG, head of Clinical Research and Development at Sandoz Pharmaceutical Corporation and head of Medical Affairs at Boehringer Ingelheim. Dr. Hartmann is currently a consultant to biotechnology and pharmaceutical companies advising them on business development transactions, strategic planning and process reengineering relevant to establishing alliances.

Victor Hartmann, MD, Chairman Life Sciences Advisory Board

Jules A. Musing

Life Sciences Advisory Board Member

Mr. Musing is the former Global Head of Biotechnology Licensing and Business Development and has been responsible for global Drug Licensing at Johnson & Johnson. In that position he negotiated and signed several multi-million dollar deals with medium and large pharmaceutical and biotechnology companies on a worldwide basis. He has more than 36 years' experience in the biotechnology and pharmaceutical industry and has been President and Managing Director of Johnson & Johnson Companies in the US and Europe, President of Ares Serono in the US and Executive Vice President for Ares Serono companies in North and Latin America. Mr. Musing has been on the Board of Johnson & Johnson Companies in Germany, France, Italy and the UK, and has been a Member of the Management Board of Ortho Biotech, (a J&J biotechnology company) in the US and Europe. He is currently Executive Chairman of Pelican Therapeutics and is a member of the Board of several companies including Delphi Digital and TherapeuticsMD.

Jules A. Musing, Life Sciences Advisory Board Member

Michael Lerner, JD

Life Sciences Advisory Board Member

Michael Lerner, Chair of Lowenstein Sandler's Life Sciences Group, has been advising pharmaceutical, life sciences and healthcare companies on key strategic matters for over 30 years. Previously, he served as VP and General Counsel at Reliant Pharmaceuticals, Inc., helping it grow into one of the nation's largest privately held pharmaceutical companies before it was acquired by GSK in 2007. As part of the senior management team, Mr. Lerner led product acquisitions and dispositions totaling in excess of $650 million, and raised more than $660 million in equity and debt. Mr. Lerner subsequently served as SVP and General Counsel of EKR Therapeutics, a specialty pharmaceutical company. Earlier in his career, Mr. Lerner was at the law firm of Gibbons PC, where he was the partner in charge of the pharmaceutical and life sciences practice. Mr. Lerner currently serves on the Board of Directors of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues, which is part of Rutgers Graduate School of Business.

Michael Lerner, JD, Life Sciences Advisory Board Member

Frederick Sancilio, MS PhD

Life Sciences Advisory Board Member

Dr. Sancilio has over 40 years of experience in the pharmaceutical research, development, manufacturing and distribution industries. Prior to founding SCI, Dr. Sancilio founded three successful pharmaceutical companies, including aaiPharma Inc., a premiere contract research organization. Dr. Sancilio is an experienced pharmaceutical executive, development scientist and accomplished entrepreneur. He has published over 20 articles in peer reviewed scientific journals, holds 14 domestic and international patents and has presented in conferences around the world. Over the course of his career, he has contributed to the development of over 1,000 drugs marketed in the United States, Europe and Asia.

Frederick Sancilio, MS PhD, Life Sciences Advisory Board Member

Kapil Dhingra, MD

Life Sciences Advisory Board Member

Dr. Kapil Dhingra was formerly Vice President and the Head of the Oncology Disease Biology Leadership Team with Hoffman-La Roche. He is an experienced oncologist, drug developer and pharmaceutical executive with a proven track record in academic research, patient care and drug development from initiation through phase IV. Prior to joining the industry, he had a successful academic career at M.D. Anderson Cancer Center. He has been a member of the Board of Directors of Micromet and Biovex. Presently, he serves on the Boards of Algeta, Exosome Diagnostics and YM Biosciences and is an advisor to a number of biotechnology and pharmaceutical companies.

Kapil Dhingra, MD, Life Sciences Advisory Board Member

Eric J. Ende, MD MBA

Life Sciences Advisory Board Member

Since 2009, Dr. Eric J. Ende has served as President of Ende BioMedical Consulting Group, which is focused on helping life sciences companies raise capital, identify licensing partners, and optimize corporate structure as well as analyzing both private and public investment opportunities for clients within the life sciences industry. In addition, Dr. Ende served with Icahn Enterprises in their Board appointment at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende was a Director on Genzyme’s Board from 2010 – 2011 until it was acquired by Sanofi-Aventis in 2011 for $20 B. During his tenure on Genzyme’s Board, he was a member of the Audit and Risk Management Committees. Dr. Ende is currently serving on the Technology Transfer Committee of Mount Sinai Innovation Partners and has served as the Chairman of the Unsecured Creditor’s Committee overseeing the Egenix Bankruptcy. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 – 2002, Dr. Ende was the senior biotechnology analyst at Banc of America Securities. And, from 1997 – 2000, he was a biotechnology analyst at Lehman Brothers. During Dr. Ende’s career as a biotechnology analyst, he was named to Institutional Investor’s All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com. Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.

Eric J. Ende, MD MBA, Life Sciences Advisory Board Member